Crinetics Pharmaceuticals (NASDAQ:CRNX) Downgraded by Lifesci Capital to Hold

08 Jul 2026, 08:42 by Scott Moore · The Cerbat Gem

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) was downgraded by equities research analysts at Lifesci Capital from a “strong-buy” rating to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

A number of other equities analysts have also issued reports on the company. JonesTrading restated a “hold” rating and issued a $85.00 target price on shares of Crinetics Pharmaceuticals in a research note on Tuesday. UBS Group initiated coverage on Crinetics Pharmaceuticals in a report on Thursday, July 2nd. They issued a “buy” rating and a $55.00 price objective on the stock. Wall Street Zen upgraded Crinetics Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a research report on Monday, April 20th. Finally, Oppenheimer reiterated a “market perform” rating on shares of Crinetics Pharmaceuticals in a report on Tuesday. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $78.27.

View Our Latest Stock Analysis on CRNX

Crinetics Pharmaceuticals Stock Up 98.7%

Shares of Crinetics Pharmaceuticals stock opened at $83.53 on Tuesday. The company has a 50 day moving average price of $37.67 and a 200 day moving average price of $41.76. The firm has a market capitalization of $8.81 billion, a P/E ratio of -16.28 and a beta of 0.23. Crinetics Pharmaceuticals has a 52 week low of $25.83 and a 52 week high of $83.63.

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.01). The company had revenue of $10.73 million for the quarter, compared to analyst estimates of $8.51 million. Crinetics Pharmaceuticals had a negative net margin of 2,747.18% and a negative return on equity of 43.96%. The company’s revenue for the quarter was up 2873.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.04) EPS. As a group, research analysts anticipate that Crinetics Pharmaceuticals will post -4.86 earnings per share for the current fiscal year.

Insider Activity

In other Crinetics Pharmaceuticals news, Director Stephanie Okey sold 6,900 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $35.67, for a total value of $246,123.00. Following the sale, the director directly owned 6,400 shares of the company’s stock, valued at approximately $228,288. This trade represents a 51.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Coelho Rogerio Vivaldi sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $40.00, for a total value of $120,000.00. Following the completion of the sale, the director owned 19,225 shares of the company’s stock, valued at $769,000. This trade represents a 13.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Crinetics Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Crinetics Pharmaceuticals by 11.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,311 shares of the company’s stock worth $1,995,000 after purchasing an additional 6,148 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Crinetics Pharmaceuticals by 6.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,581 shares of the company’s stock valued at $11,658,000 after buying an additional 22,305 shares in the last quarter. Strs Ohio purchased a new position in Crinetics Pharmaceuticals in the 1st quarter valued at about $124,000. Invesco Ltd. raised its holdings in shares of Crinetics Pharmaceuticals by 11.7% during the second quarter. Invesco Ltd. now owns 78,140 shares of the company’s stock valued at $2,247,000 after acquiring an additional 8,181 shares during the last quarter. Finally, Sei Investments Co. lifted its position in shares of Crinetics Pharmaceuticals by 20.6% in the second quarter. Sei Investments Co. now owns 60,180 shares of the company’s stock valued at $1,731,000 after acquiring an additional 10,269 shares in the last quarter. 98.51% of the stock is owned by hedge funds and other institutional investors.

Crinetics Pharmaceuticals News Summary

Here are the key news stories impacting Crinetics Pharmaceuticals this week:

Positive Sentiment: Vertex announced a definitive agreement to buy Crinetics for $85 per share in cash, giving shareholders a large acquisition premium and driving the stock sharply higher.
Positive Sentiment: The deal highlights Crinetics’ approved rare-disease drug PALSONIFY and late-stage pipeline candidate Atumelnant, which made the company attractive as a strategic asset.
Positive Sentiment: Several brokerages raised or reaffirmed favorable price targets around the deal price, signaling that analysts see limited downside near the acquisition value.

Crinetics Pharmaceuticals Company Profile

(Get Free Report)

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.